How Mounjaro Works: the Mechanism Behind the Weight Loss

The common misconception: Mounjaro is not a simple appetite suppressant

Most people assume Mounjaro works the way an old-fashioned diet pill does, it tells your brain you are full and you eat less. That is part of the picture, but it misses what makes tirzepatide different. The bigger story is that it mimics two gut hormones your body already produces: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both are released naturally after eating. Both carry signals about energy intake, blood sugar and satiety. Mounjaro activates receptors for both at once.

Why does that matter? Earlier GLP-1 medicines (including semaglutide, the active ingredient in Wegovy) target only the GLP-1 receptor. Tirzepatide adds the GIP pathway. In clinical trials, that dual activation produced meaningfully greater average weight loss than semaglutide, as the head-to-head SURMOUNT-5 trial published in the New England Journal of Medicine (2025) confirmed. You can read the underlying mechanism detail on the tirzepatide mechanism page if you want the pharmacology at a deeper level.

The short version: Mounjaro is not a stimulant, not a fat-blocker and not a mood-altering drug, and understanding exactly what it does helps explain why it works so differently from older weight-loss approaches. It works by fitting into hormone receptors that already exist in your gut, pancreas and brain, and switching on signals your body already understands. That biological basis is why it needs a prescriber's oversight, not just a checkout cart.

What those hormone signals actually do once activated

Once tirzepatide binds to GIP and GLP-1 receptors, several things happen in parallel. The pancreas releases more insulin in response to glucose, which is why the medicine also has a licence for type 2 diabetes. Glucagon (a hormone that raises blood sugar between meals) is suppressed. And, critically for weight management, signals travel to the brain's appetite-regulating centres reporting that energy is available and another meal is not yet needed.

At the same time, gastric emptying slows. Food sits in the stomach longer than it normally would. The mechanical stretch of a smaller meal lasts longer, reinforcing the hormonal signal. People on Mounjaro frequently describe eating a third of what they used to and feeling genuinely satisfied, not white-knuckling a diet. That is not self-discipline; it is the receptor activity doing its job.

If you want to understand how Mounjaro works across each of these biological pathways, that page covers the pancreatic effects and more in detail. The Mounjaro overview page is also a useful starting point if you are earlier in your research.

One practical note on timing: people sometimes ask whether it matters which day of the week they inject. Broadly, no, consistency is what counts. Our prescribers hear this question most often from people who start treatment around a bank holiday and worry about disrupting the schedule. Your Patient Information Leaflet covers flexibility; specific guidance always comes from your prescriber, not a general page like this one.

Where the trial evidence puts this mechanism into practice

Understanding the mechanism only goes so far. The question most people actually want answered is: what does this translate to in real weight loss? In the SURMOUNT-1 trial (which ran for 72 weeks and included over 2,500 adults with obesity) participants on the highest tirzepatide dose saw an average body-weight reduction of around 20–21%. That is a figure the NICE technology appraisal TA1026 reviewed before recommending tirzepatide for use in England.

Results in a trial setting do not guarantee what any individual will experience. Mounjaro is licensed as an adjunct to a reduced-calorie diet and increased physical activity, the mechanism supports those lifestyle changes, it does not replace them. If weight loss is less than 5% after six months at the highest tolerated dose, the prescriber reviews whether continuing makes sense.

Eligibility for Mounjaro is set by the prescriber after assessing the full picture: BMI, any weight-related conditions, other medicines, and medical history. The licensed threshold is a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, raised cholesterol or type 2 diabetes. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. For context on how NHS access compares with the private route, the tirzepatide information page sets out both pathways, and our Mounjaro tariffs page explains what private treatment costs and how pricing is structured. If you are ready to find out whether Mounjaro is clinically suitable for you, the next step is a free consultation with our prescribers.

Side effects that follow from the mechanism

Because Mounjaro slows gastric emptying and affects gut-hormone signalling, most of its side effects are gastrointestinal. Nausea, loose stools, constipation, indigestion and burping are the most frequently reported, particularly after starting treatment or after a dose increase, when the body is adjusting to a new level of receptor activity. These effects typically settle within days to a couple of weeks for most people.

The gradual dose-escalation schedule exists precisely because of this. Starting at 2.5 mg gives the system time to adapt before the dose moves upward. Rarer but more serious effects include acute pancreatitis: the MHRA has highlighted severe, persistent stomach pain (especially if it radiates toward the back) as a reason to seek urgent medical attention, regardless of whether vomiting is present. The NHS tirzepatide medicine page lists the full side-effect profile as it is published in the Summary of Product Characteristics.

Women using oral contraceptives should be aware that absorption of the pill may be reduced during the first four weeks of Mounjaro treatment and for four weeks after each dose increase; adding a barrier method during those windows is the standard advice. This follows from the gastric-emptying effect directly, it is the mechanism creating a practical consideration, not a separate pharmacological issue. Speak to your prescriber or GP about your specific contraceptive needs. The nume FAQs cover several of the questions our team fields most often on this topic.